| US 7,615,213 B2 | ||
| Antibodies against human interleukin-13 and pharmaceutical compositions thereof | ||
| Marion T. Kasaian, Charlestown, Mass. (US); Lioudmila Tchistiakova, Andover, Mass. (US); Geertruida M. Veldman, Sudbury, Mass. (US); Kimberly Ann Marquette, Somerville, Mass. (US); Xiang-Yang Tan, Reading, Mass. (US); Debra D. Donaldson, Medford, Mass. (US); Laura Long Lin, Weston, Mass. (US); Tania Shane, Newton, Mass. (US); Amy Sze Pui Tam, Medford, Mass. (US); Eric Feyfant, Lexington, Mass. (US); Nancy L. Wood, Somerville, Mass. (US); Lori J. Fitz, Somerville, Mass. (US); Angela M. Widom, Acton, Mass. (US); Kevin D. Parris, Auburndale, Mass. (US); Samuel J. Goldman, Acton, Mass. (US); and Jose W. Saldanha, Middlesex (United Kingdom) | ||
| Assigned to Wyeth, Madison, N.J. (US) | ||
| Filed on Jun. 09, 2005, as Appl. No. 11/149,309. | ||
| Claims priority of provisional application 60/578473, filed on Jun. 09, 2004. | ||
| Claims priority of provisional application 60/581375, filed on Jun. 22, 2004. | ||
| Claims priority of provisional application 60/578736, filed on Jun. 09, 2004. | ||
| Prior Publication US 2006/0063228 A1, Mar. 23, 2006 | ||
| Int. Cl. A61K 39/395 (2006.01) | ||
| U.S. Cl. 424—133.1 [424/145.1; 530/387.3; 530/388.23] | 85 Claims |
| 1. A purified antibody, or antigen-binding fragment thereof, comprising a heavy chain immunoglobulin variable domain and a
light chain immunoglobulin variable domain that binds to IL-13 with a KD of less than 10−7 M as determined by surface plasmon resonance (SPR), wherein the light chain immunoglobulin variable domain comprises the amino
acid sequence of:
(i) KASESVDNYGKSLMH (SEQ ID NO:19), in CDR1,
(ii) RASNLES (SEQ ID NO:20), in CDR2, and
(iii) QQSNEDPWT (SEQ ID NO:21), in CDR3;
and wherein the heavy chain immunoglobulin variable domain comprises the amino acid sequence of:
(i) SYAMS (SEQ ID NO:22), in CDR1,
(ii) SISSGGNTYYPDSVKG (SEQ ID NO:23), in CDR2, and
(iii) LDGYYFGFAY (SEQ ID NO:24), in CDR3,
or an amino acid sequence that differs by fewer than three conservative amino acid substitutions from the amino acid sequence
of any of SEQ ID NO:19-24; and
wherein the light chain immunoglobulin variable domain, with or without said conservative amino substitutions, contacts IL-13
with residues ASN31 (CDR1), TYR32 (CDR1), LYS34 (CDR1), ARG54 (CDR2), ASN96 (CDR3), ASP98 (CDR3), and TRP100 (CDR3), of SEQ
ID NO:11, 12, or 35, and the heavy chain immunoglobulin variable domain, with or without said conservative amino substitutions,
contacts IL-13 with residues ILE30, SER31 (CDR1), ALA33 (CDR1), TRP47, SER50 (CDR2), SER52 (CDR2), SER53 (CDR2), TYR58 (CDR2),
LEU98 (CDR3), ASP99 (CDR3), GLY100 (CDR3), TYR101 (CDR3), TYR102 (CDR3), and PHE103 (CDR3), of SEQ ID NO:15, 16 or 36.
|